Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Chingiz Underbayev, MD PhD, Inhye E Ahn, MD, Hailey Harris, Lauren T Vaughn, Mehdi Pirooznia, MD PhD, Liqiang Xi, MD, Mark Raffeld, MD, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 1287.

https://doi.org/10.1182/blood-2019-127364

Published: 2019

Journal Articles

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

Blood (2012) 120 (21): 732.

https://doi.org/10.1182/blood.V120.21.732.732

Published: 2012

Journal Articles

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Robert J. Kreitman, MD, Liqiang Xi, MD, Winnifred Navarro, BS, Maryalice Stetler-Stevenson, MD, PhD, Evgeny Arons, PhD, Mark Raffeld, MD

Blood (2011) 118 (21): 931.

https://doi.org/10.1182/blood.V118.21.931.931

Published: 2011

Journal Articles

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Adriana Zingone, MD, PhD, Neha Korde, MD, Jinqiu Chen, PhD, Liqiang Xi, MD, Mark Raffeld, MD, Beata Holkova, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, Austin Doyle, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Christina Annunziata, MD, PhD, Steven Grant, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 306.

https://doi.org/10.1182/blood.V118.21.306.306

Published: 2011

NARROW

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Whole Exome Sequencing Reveals Multiple Driver Events in Chronic Lymphocytic Leukemia Patients with Acquired Ibrutinib Resistance

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only